



Loris De Cecco

Contact

Loris De Cecco

Publications (6)

Pizzamiglio S, Huober J, Ellard S, Rimm D, Gombos A, Daidone M, Verderio P, Tagliabue E, Di Cosimo S, Nuciforo P, Bajji M, Cosentino G, Ciniselli C, De Cecco L, Cataldo A, Plantamura I, Triulzi T, El-Abed S, Wang Y, Iorio M. What if the future of HER2-positive breast cancer patients was written in miRNAs? An exploratory analysis from NeoALTTO study. *Cancer Med* 2021; 11:332-339.

Pizzamiglio S, Cappelletti V, Cinieri S, Piccart M, Daidone M, Pruneri G, Colombo M, Tagliabue E, Verderio P, Huober J, Nuciforo P, Izquierdo M, Ciniselli C, Triulzi T, Gargiuli C, De Cecco L, de Azambuja E, Fumagalli D, Sotiriou C, Harbeck N, Di Cosimo S. Integrated Molecular and Immune Phenotype of HER2-Positive Breast Cancer and Response to Neoadjuvant Therapy: A NeoALTTO Exploratory Analysis. *Clin Cancer Res* 2021; 27:6307-6313.

Di Cosimo S, Gori S, Cinieri S, Torri V, Baselga J, Piccart M, de Braud F, Apolone G, Verderio P, Huober J, Daidone M, Peña L, Triulzi T, Pizzamiglio S, De Cecco L, de Azambuja E, Fumagalli D, Putzai L, Harbeck N, Izquierdo M, Tagliabue E. The 41-gene classifier TRAR predicts response of HER2 positive breast cancer patients in the NeoALTTO study. *Eur J Cancer* 2019; 118:1-9.

Siano M, Espeli V, Mach N, Bossi P, Licitra L, Ghielmini M, Frattini M, Canevari S, De Cecco L. Gene signatures and expression of miRNAs associated with efficacy of panitumumab in a head and neck cancer phase II trial. *Oral Oncol* 2018; 82:144-151.

Bossi P, Licitra L, Canevari S, Locati L, Pilotti S, Perrone F, Marchesi E, Paoli A, Tonella L, Giannoccaro M, Sponghini A, Cossu Rocca M, Bergamini C, Siano M, De Cecco L. Are Fusion Transcripts in Relapsed/Metastatic Head and Neck Cancer Patients Predictive of Response to Anti-EGFR Therapies?. *Dis Markers* 2017; 2017:6870614.

Bossi P, Canevari S, Licitra L, Locati L, Pilotti S, Perrone F, Cortelazzi B, Marchesi E, Giannoccaro M, Favales F, Sponghini A, Cossu Rocca M, Siano M, Bergamini C, De Cecco L. Functional Genomics Uncover the Biology behind the Responsiveness of Head and Neck Squamous Cell Cancer Patients to Cetuximab. *Clin Cancer Res* 2016; 22:3961-70.

Projects (0)

No results found.

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

support.forschung@kssg.ch